Psyence Biomedical (NASDAQ:PBM) Releases Earnings Results

Psyence Biomedical (NASDAQ:PBM) posted its quarterly earnings results on Monday. The company reported ($0.40) earnings per share for the quarter, FiscalAI reports.

Psyence Biomedical Stock Performance

Shares of NASDAQ:PBM opened at $2.91 on Wednesday. The company has a market capitalization of $2.97 million, a PE ratio of 0.11 and a beta of 1.64. The stock has a fifty day moving average of $4.88 and a 200-day moving average of $4.53. Psyence Biomedical has a one year low of $1.92 and a one year high of $74.94.

Institutional Trading of Psyence Biomedical

An institutional investor recently raised its stake in Psyence Biomedical stock. Virtu Financial LLC grew its position in Psyence Biomedical Ltd. (NASDAQ:PBM) by 258.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 37,042 shares of the company’s stock after buying an additional 26,717 shares during the period. Virtu Financial LLC owned 3.63% of Psyence Biomedical worth $28,000 at the end of the most recent reporting period. 77.44% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on PBM shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Psyence Biomedical in a report on Tuesday, April 21st. Wall Street Zen raised shares of Psyence Biomedical to a “hold” rating in a research report on Saturday, June 6th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Psyence Biomedical presently has an average rating of “Sell”.

About Psyence Biomedical

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.